Reduced Expression of METTL3 Promotes Metastasis of Triple-Negative Breast Cancer by m6A Methylation-Mediated COL3A1 Up-Regulation

Yu Shi, Chunlei Zheng, Yue Jin, Bowen Bao, Duo Wang, Kezuo Hou, Jing Feng, Shiying Tang, Xiujuan Qu, Yunpeng Liu, Xiaofang Che, Yuee TengFrontiers in Oncology 2020 · DOI

TL;DR

This study reveals that reduced expression of the RNA-modifying enzyme METTL3 promotes metastasis in triple-negative breast cancer (TNBC) by upregulating COL3A1. This finding highlights METTL3 as a potential therapeutic target for TNBC, offering a new avenue for treatment strategies.

What Problem Does This Paper Address?

Triple-negative breast cancer (TNBC) is a particularly aggressive form of breast cancer with a poor prognosis, largely due to its high propensity for metastasis. While epigenetic modifications, including RNA methylation (specifically N6-methyladenosine or m6A), are known to play a role in cancer development, the specific mechanisms and key players in TNBC metastasis remain unclear. This paper aims to identify which m6A modulators are critical in TNBC metastasis and elucidate the molecular pathways involved, addressing the knowledge gap regarding the role of RNA methylation in this aggressive cancer subtype.

Methods

The researchers employed a multi-pronged approach:

  • Bioinformatics Analysis: They utilized online databases like KM plotter and GEPIA to analyze the expression levels of several m6A modulators (METTL3, METTL14, WTAP, FTO, ALKBH5) and their correlation with prognosis (specifically distance-metastasis-free survival, DMFS) in breast cancer, with a focus on TNBC.
  • Cell Culture and Manipulation: Standard human TNBC cell lines (MDA-MB-231 and MDA-MB-468) were used. Techniques included:
  • Knockdown (KD): Using siRNAs to reduce the expression of METTL3 and COL3A1.
  • Overexpression (OE): Using plasmids to increase the expression of METTL3.
  • Pharmacological Inhibition: Using cycloleucine, a known inhibitor of m6A modification.
  • Functional Assays: To assess metastatic potential, the researchers performed:
  • Trans-well Migration and Invasion Assays: To measure the ability of cells to move through a porous membrane.
  • Cell Adhesion Assays: To quantify how well cells attach to surfaces.
  • Molecular Techniques:
    • Quantitative Real-Time PCR (qRT-PCR): To measure mRNA expression levels of METTL3, COL3A1, and MYH11.
  • Western Blot: To detect protein levels of METTL3 and COL3A1.
  • Methylated RNA Immunoprecipitation followed by qRT-PCR (MeRIP-qRT-PCR): To specifically assess the m6A modification levels of COL3A1 mRNA.
  • Enzyme-Linked Immunosorbent Assay (ELISA): To quantify the secretion levels of Collagen $\alpha$1(III).
  • Immunohistochemistry (IHC): Performed on tissue microarrays (TMAs) of breast cancer samples to examine the expression of METTL3 and COL3A1 in situ and correlate it with patient survival.

Datasets

  • TCGA (The Cancer Genome Atlas) and GTEx (Genotype-Tissue Expression) databases: Used for analyzing mRNA expression levels of m6A modulators in breast cancer tissues versus normal tissues.
  • KM plotter: Utilized for Kaplan-Meier survival analysis to assess the association between gene expression (m6A modulators, COL3A1) and distant-metastasis-free survival (DMFS) or overall survival (OS).
  • m6Avar database: Used to identify genes with potential m6A modification sites.
  • Shanghai Outdo Biotechnology Company TMA dataset: A collection of breast cancer tissue microarrays used for immunohistochemistry and survival analysis.

Key Insights and Ideas

  • METTL3 as a TNBC Metastasis Suppressor: Unlike some other cancers where METTL3 might promote tumorigenesis, this study strongly implicates METTL3 as a suppressor of metastasis specifically in TNBC. Its low expression is linked to poor prognosis.
  • COL3A1 as a Key Downstream Target: The research pinpoints Collagen type III alpha 1 chain (COL3A1) as a critical target gene of METTL3. METTL3's ability to inhibit metastasis is directly tied to its regulation of COL3A1.
  • m6A Methylation as the Regulatory Mechanism: The study demonstrates that METTL3 exerts its effect by increasing m6A methylation on COL3A1 mRNA, which in turn leads to its downregulation. This highlights a specific epigenetic mechanism driving metastasis.
  • TNBC Specificity: The negative correlation between METTL3 and COL3A1 expression, and thus the metastasis-inhibitory role of METTL3, appears to be specific to TNBC, suggesting that cancer subtype heterogeneity is crucial in understanding m6A modulator functions.

Key Results

  • Low METTL3 Expression in TNBC: Bioinformatics analysis revealed significantly lower expression of METTL3 in breast cancer tissues compared to normal tissues, and this low expression was associated with shorter distance-metastasis-free survival (DMFS) in TNBC patients.
  • METTL3 Knockdown Enhances Metastasis: In TNBC cell lines, knockdown of METTL3 significantly increased cell migration, invasion, and adhesion capabilities.
  • COL3A1 Upregulation by METTL3 KD: Knockdown of METTL3 led to a significant upregulation of COL3A1 mRNA and protein levels.
  • METTL3 Downregulates COL3A1 via m6A: MeRIP-qRT-PCR showed that METTL3 knockdown reduced m6A enrichment on COL3A1 mRNA. Overexpression of METTL3 decreased COL3A1 expression, an effect partially reversed by the m6A inhibitor cycloleucine.
  • COL3A1 Promotes TNBC Metastasis: Knockdown of COL3A1 significantly suppressed migration, invasion, and adhesion in TNBC cells. High COL3A1 expression was also associated with shorter DMFS in TNBC patients.
  • Inverse Correlation in TNBC Tissues: Immunohistochemistry on TMA sections confirmed a significant negative correlation between METTL3 and COL3A1 expression in TNBC tissues, but not in non-TNBC tissues.

Limitations and Future Work

  • Multiple Target Genes: The study identified COL3A1 as a key target, but acknowledges that METTL3 likely regulates other genes involved in TNBC metastasis. Further investigation into these additional targets is warranted.
  • Specific m6A Sites: While the study demonstrates METTL3-mediated m6A modification of COL3A1, the precise m6A modification sites on COL3A1 mRNA were not identified. Future work could involve MeRIP-sequencing to pinpoint these sites and clarify the exact mechanism of COL3A1 mRNA regulation.
  • Clinical Validation: While TMA data provided clinical correlation, larger-scale clinical studies would further validate these findings and the potential of METTL3 and COL3A1 as prognostic biomarkers.
  • Mechanism of COL3A1 in Metastasis: The study shows COL3A1 promotes metastasis, but the detailed molecular mechanisms by which COL3A1 contributes to TNBC metastasis require further exploration.

Summary updated

Abstract

The abnormal m6A modification caused by m6A modulators is a common feature of various tumors; however, little is known about which m6A modulator plays the most important role in triple-negative breast cancer (TNBC). In this study, when analyzing the influence of m6A modulators (<i>METTL3, METTL14, WTAP, FTO</i>, and <i>ALKBH5</i>) on the prognosis of breast cancer, especially in TNBC using several on-line databases, methyltransferase-like 3 (<i>METTL3</i>) was found to have low expression in breast cancer, and was closely associated with short-distance-metastasis-free survival in TNBC. Further investigation showed that knockdown of <i>METTL3</i> could enhance the ability of migration, invasion, and adhesion by decreasing m6A level in TNBC cell lines. Collagen type III alpha 1 chain (<i>COL3A1</i>) was identified and verified as a target gene of <i>METTL3</i>. <i>METTL3</i> could down-regulate the expression of <i>COL3A1</i> by increasing its m6A methylation, ultimately inhibiting the metastasis of TNBC cells. Finally, with immunohistochemistry staining in breast cancer tissues, it was proved that <i>METTL3</i> expression was negatively correlated with <i>COL3A1</i> in TNBC, but not in non-TNBC. This study demonstrated the potential mechanism of m6A modification in metastasis and provided potential targets for treatment in TNBC.
BibTeX
@inproceedings{shi2020reduced,
  author = {Yu Shi and Chunlei Zheng and Yue Jin and Bowen Bao and Duo Wang and Kezuo Hou and Jing Feng and Shiying Tang and Xiujuan Qu and Yunpeng Liu and Xiaofang Che and Yuee Teng},
  title = {{Reduced Expression of METTL3 Promotes Metastasis of Triple-Negative Breast Cancer by m6A Methylation-Mediated COL3A1 Up-Regulation}},
  booktitle = {Frontiers in Oncology},
  year = {2020},
  doi = {10.3389/fonc.2020.01126},
}
Figure